Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors

Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis

(2021) Monika D. Scuron et al.   Frontiers in Immunology

Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies

(2021) Kim Papp et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis

(2021) Thomas Bieber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders

(2021) Jonathan I. Silverberg et al.   JAMA Dermatology

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

(2021) Kristian Reich et al.   LANCET

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

(2021) Emma Guttman-Yassky et al.   LANCET

Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study

(2021) Hidemi Nakagawa et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials

(2020) E.L. Simpson et al.   BRITISH JOURNAL OF DERMATOLOGY

Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study

(2020) Hidemi Nakagawa et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders

(2020) Satoru Noji et al.   JOURNAL OF MEDICINAL CHEMISTRY

Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus

(2020) Kenji Kabashima et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis

(2020) Jonathan I. Silverberg et al.   JAMA Dermatology

Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis

(2020) Kristian Reich et al.   JAMA Dermatology

Effects of Delgocitinib Ointment 0.5% on the Normal Mouse Skin and Epidermal Tight Junction Proteins in Comparison With Topical Corticosteroids

(2020) Akiko Anagawa-Nakamura et al.   TOXICOLOGIC PATHOLOGY

Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis

(2019) Hidemi Nakagawa et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial

(2019) Emma Guttman-Yassky et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model

(2019) Yasuo Yamamoto et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Long‐term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis

(2019) Hidemi Nakagawa et al.   JOURNAL OF DERMATOLOGY

Interleukin-31 and interleukin-31 receptor: New therapeutic targets for atopic dermatitis

(2018) Chisa Nakashima et al.   EXPERIMENTAL DERMATOLOGY

Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis

(2018) Hidemi Nakagawa et al.   JOURNAL OF DERMATOLOGY

Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study

(2018) Emma Guttman-Yassky et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

OUP accepted manuscript

(2018)   RHEUMATOLOGY

The interplay between genetic and environmental factors in the pathogenesis of atopic dermatitis

(2017) Atsushi Otsuka et al.   IMMUNOLOGICAL REVIEWS

The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies

(2017) Patrick M. Brunner et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Therapeutic pipeline for atopic dermatitis: End of the drought?

(2017) Amy S. Paller et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial

(2016) R. Bissonnette et al.   BRITISH JOURNAL OF DERMATOLOGY

The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization

(2015) Shinji Noda et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling

(2015) Wataru Amano et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo

(2014) Atsuo Tanimoto et al.   INFLAMMATION RESEARCH

Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis

(2014) Lisa A. Beck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Th17 cells and tissue remodeling in atopic and contact dermatitis

(2013) D. Simon et al.   ALLERGY

The Epithelial Cell-Derived Atopic Dermatitis Cytokine TSLP Activates Neurons to Induce Itch

(2013) Sarah R. Wilson et al.   CELL

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

(2010) A. Quintas-Cardama et al.   BLOOD

Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050

(2010) J. S. Fridman et al.   JOURNAL OF IMMUNOLOGY

Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection

(2010) Mark E. Flanagan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Structures and biological functions of IL-31 and IL-31 receptors

(2008) Qing Zhang et al.   CYTOKINE & GROWTH FACTOR REVIEWS